Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

<p class="first" id="d1756924e213">Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 (177Lu)-PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment. </p>

Related collections

Author and article information

Contributors

Oliver Sartor: (View ORCID Profile)

Journal

Title: New England Journal of Medicine

Abbreviated Title: N Engl J Med

Publisher: Massachusetts Medical Society

ISSN (Print): 0028-4793

ISSN (Electronic): 1533-4406

Publication date (Electronic): June 23 2021

Affiliations

[1 ]From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany;...

Article

DOI: 10.1056/NEJMoa2107322

PMC ID: 8446332

PubMed ID: 34161051

SO-VID: 4ed13d19-5e09-4121-9067-c50c5d3e7469

License:

http://www.nejmgroup.org/legal/terms-of-use.htm

History

Data availability:

Comments

Comment on this article

scite_

Cited by 604

See all cited by

- Version 1